Business
10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell an
About this update from 10x Genomics, Inc.
[{"type":"text","content":"Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology","length":221,"tagName":"p","attribs":{}},{"type":"text","content":"10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.","length":642,"tagName":"p"},{"type":"image","alt":"10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)","displaySize":"","headline":null,"caption":"10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/0862b7da135f6592c758a7fd225e5c41"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ngkNiIWWETdTothBh84MZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/0862b7da135f6592c758a7fd225e5c41","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1700607/10x_Genomics_Logo_V1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The study with Dana-Farber intends to examine samples from hundreds of patients to evaluate therapeutic targets and relevant tumor microenvironment features for the most promising emerging therapies in oncology, including antibody-drug conjugates (ADCs), radioligand therapies (RLTs), bispecific antibodies, immune checkpoint inhibitors and other precision approaches. These treatments are reshaping the standard of care, yet patients can experience dramatically different outcomes. By understanding why patients r...